New Phase 3 Clinical Trial Opens for Pediatric, Adult Hodgkin Lymphoma Patients - Report - MDSpire
Advertisement
New Phase 3 Clinical Trial Opens for Pediatric, Adult Hodgkin Lymphoma Patients
While an estimated 95% of “younger” patients diagnosed with Hodgkin lymphoma are still alive and into survivorship within five years of their diagnosis, their long-term health suffers from the aggressive treatment needed to fight the disease.
Phase 3 Trial Tests Immunotherapy to Reduce Toxicity in Early-Stage Hodgkin Lymphoma
Overview
A new Phase 3 clinical trial (AHOD2131) is evaluating whether adding immunotherapy can reduce the intensity and long-term toxicities of conventional chemotherapy and radiation in pediatric and adult patients with stage 1 or 2 Hodgkin lymphoma. The trial aims to maintain high survival rates while minimizing treatment-related complications.
Background
Hodgkin lymphoma has excellent short-term survival, with over 95% of younger patients alive at five years post-diagnosis. However, aggressive treatments often cause severe long-term complications such as secondary cancers and cardiovascular disease, increasing mortality over decades. Current therapies include chemotherapy regimens like ABVD and radiation, both contributing to toxicity. There is a critical need to develop treatment protocols that reduce these risks without compromising efficacy.
Data Highlights
Trial Feature
Details
Patient Population
Stage 1 or 2 Hodgkin lymphoma, ages 5-60
Trial Type
Phase 3, randomized
Standard Arm
ABVD chemotherapy cycles based on risk and response
Involved site RT for ~15% with slow early response
Accrual Goal
1,875 patients over 5 years
Sites
300+ including Roswell Park
Key Findings
Long-term mortality in Hodgkin lymphoma survivors is increased due to treatment-related toxicities.
AHOD2131 trial incorporates immunotherapy (brentuximab vedotin + nivolumab) to reduce chemotherapy and radiation exposure.
Patients start with 2 cycles of ABVD, then PET CT determines rapid vs slow responders for treatment randomization.
Only about 15% of patients are expected to require radiation therapy, a significant reduction from historical rates.
The trial includes correlative studies using PET volumetrics and AI to better assess treatment response.
Patient-reported outcomes are collected to evaluate regimen tolerability.
Clinical Implications
This trial may establish a new standard of care by reducing exposure to toxic chemotherapy agents and radiation, potentially lowering the incidence of long-term complications in early-stage Hodgkin lymphoma patients. Clinicians should consider referring eligible patients aged 5 to 60 for enrollment to access this promising immunotherapy-based approach. Monitoring response with advanced imaging and patient-reported outcomes will enhance personalized treatment decisions.
Conclusion
The AHOD2131 trial represents a significant effort to improve long-term survivorship in Hodgkin lymphoma by integrating immunotherapy to minimize treatment toxicity while maintaining excellent cure rates. Its large scale and collaborative design offer hope for safer, more effective therapies.
References
Kara Kelly, MD / Roswell Park Comprehensive Cancer Center / 2024 -- New Phase 3 Clinical Trial Opens for Pediatric, Adult Hodgkin Lymphoma Patients
